Ozempic (semaglutide) is a well-known prescription drug that’s used to treat blood sugar of people with type 2 diabetes, has been hailed for its many benefits including weight loss and lowering risk of many chronic diseases.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

While plenty of people rave about the weight loss results you can get from drugs like Ozempic, there’s also been a ton of chatter over the fact that these meds are really expensive. These drugs have also been in and out of shortage, making it tough to get your hands on Ozempic and similar medications—if you can afford it.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may have overestimated the market for its new weight-loss and diabetes medicines.

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs Wegovy and Ozempic, its CFO Karsten Munk Knudsen told a media

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said. The company is still "evaluating" the price of the drug,